Results released for Entresto® Phase III PARAGON-HF trial in heart failure
Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will be presented in September at the ESC Congress 2019, the annual meeting of the […]